2014 Healthcare Prescription 
World of DTC Marketing
MARCH 31, 2022
Under the bill proposed, Medicare beneficiaries and those insured through private plans would pay no more than $35 for a 30-day insulin prescription, or the lesser of $35 or 25% of the plan’s negotiated price for a 30-day prescription. In 2014, researchers determined, 30% of insulin revenue went to middlemen.
World of DTC Marketing
JANUARY 4, 2022
In 2014, cancer patients paid $4 billion out-of-pocket for cancer treatment. These cost estimates include cancer-attributable costs for medical services and oral prescription drugs. Cancer patients may struggle to pay out-of-pocket expenses due to the high expenses incurred, the medical debt, or loss of work. population.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
SEPTEMBER 7, 2022
In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. While that sounds encouraging, most cancer drugs launched between 2009 and 2014 cost more than USD 100,000 annually. Biogen’s failure should be a warning to other pharma companies.
pharmaphorum
NOVEMBER 14, 2022
It is only right that healthcare takes a strong stance in reducing the impact of climate change. Healthcare’s contribution to the world’s carbon footprint is significant in its own right and is estimated at 4.4% He is involved in numerous projects related to ESG, as well as the interface between healthcare and digital technology.
European Pharmaceutical Review
JULY 4, 2024
1 For use as prescription drugs, a botanical product must be approved by the FDA: to date, only two have gained this approval. 2 Approach taken by regulators in the UK The Medicines and Healthcare products Regulatory Agency regulates herbal medicines in the UK. 13 Currently, over 350 herbal remedies have been granted a THR licence.
Legacy MEDSearch
JUNE 15, 2023
The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its direct-to-home digital durable medical equipment (DME) platform is reshaping the delivery of prescription therapies.
Pharmaceutical Technology
JANUARY 6, 2023
The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. This class-action litigation specifically focused on a 2011 licensing agreement between the two companies. These actions allegedly led to the extension of Novartis’ patents.
Expert insights. Personalized for you.
240 
Let's personalize your content